Teva Pharmaceutical Industries Limited Announces Launch of Generic Zemplar® in the United States
Published: Oct 01, 2013
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of the generic equivalent to Zemplar® (paricalcitol) tablets in the United States as of September 30, 2013. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
Help employers find you! Check out all the jobs and post your resume.